Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034007 | 0.92 | ALDH1A1 (0.49) | GRM5SRCALDH1A1PTGS1PTGS2 | |
| SCHEMBL15046477 | 0.91 | GRM5 (0.43) | GRM5SRCGABRA2GABRB2ALDH1A1 | |
| SCHEMBL15046474 | 0.90 | ALDH1A1 (0.45) | GRM5SRCGABRA2GABRB2ALDH1A1 | |
| SCHEMBL15033933 | 0.89 | PTGS1 (0.41) | GRM5GABRA2GABRB2ALDH1A1PTGS1 | |
| SCHEMBL15033983 | 0.87 | GABRA2 (0.48) | GRM5SRCGABRA2GABRB2ALDH1A1 | |
| SCHEMBL15033978 | 0.87 | GABRA2 (0.43) | GABRA2GABRB2PTGS1PTGDR2MAPT | |
| SCHEMBL15034001 | 0.86 | MAPT (0.51) | GABRA2GABRB2PTGS1MAPTAGER | |
| SCHEMBL15019885 | 0.85 | GABRA2 (0.42) | GABRA2GABRB2PTGS1PTGDR2MAPT | |
| SCHEMBL15046450 | 0.83 | ALDH1A1 (0.55) | GRM5SRCALDH1A1MAPTCA1 | |
| SCHEMBL15034000 | 0.81 | ALDH1A1 (0.48) | GRM5SRCGABRA2GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791118-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158011-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | GRM5 1/4885SRC 4087/4885GABRA2 84/4885 |
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | GRM5 1/4885SRC 4137/4885GABRA2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.